Dr. Alva on Results of the CABOSUN Trial in RCC

Ajjai Shivaram Alva, MBBS, an associate professor at the University of Michigan, discusses the results of the CABOSUN trial in renal cell carcinoma (RCC).

The randomized, phase II CABOSUN trial compared the multikinase inhibitor cabozantinib (Cabometyx) with sunitinib (Sutent) as a frontline treatment for patients with advanced RCC, explains Alva. The study, which had a primary endpoint of progression-free survival (PFS) by investigator assessment, demonstrated that cabozantinib is superior to sunitinib in patients with intermediate- or poor-risk RCC by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria, says Alva.

The CABOSUN trial has been validated by independent observers and assessments, continuing to show that cabozantinib, in terms of PFS and response rate, is a superior choice over sunitinib in patients with intermediate- or poor-risk RCC by IMDC criteria, concludes Alva.